toktok newsletter will keep you up-to-date with the latest news on SK and member companies.
On January 11 (local time), SK Inc. held a SK Bio Night at the Four Seasons Hotel in San Francisco, US, with the attendance of over 100 executives from 50 plus business enterprises including SK Inc., SK bio and pharmaceutical member companies, SK’s global partners and investment companies.
The event was attended by the newly appointed management leadership of SK Inc.’s bio and pharmaceutical business including Vice Chairman & CEO Jang Dong-hyun of SK Inc., CEO Lee Dong-hoon of SK biopharmaceuticals, CEO Joerg Ahlgrimm of SK pharmteco, and Kim Yeon-tae, Head of SK Bio Investment Center, who shared their future business vision. They also presented sales pitches to expand their global business, strengthening collaborative ties with investors and partners.
Kim Yeon-tae, Head of Bio Investment Center at SK Inc., presented the company’s activities and future vision for expanding its business footprint beyond a small-molecule drug-focused portfolio into the realm of biopharmaceuticals.
CEO Lee Dong-hoon of SK biopharmaceuticals that had successfully rolled out its anti-seizure medication cenobamate, which is now commercially available in the U.S. under the brand name XCOPRI®, provided updates on how cenobamate is doing in the global market and the company’s strategy to build up next-gen innovative new drug pipelines.
SK pharmteco has been evolving as a global contract development and manufacturing organization (CDMO) after successfully entering the cell and gene therapy (CGT) sector, an emerging growth market in the CDMO sector. Joerg Ahlgrimm, CEO of SK pharmteco, unveiled the company’s business strategy as a global CDMO along with its vision and competitiveness to investors and partners at the event.
Through SK Bio Night, SK Inc. plans to hold a series of global networking events targeting the bio-business sector in a bid to identify various business partnership and investment opportunities in the global market, including the U.S.